Second, effective targeting of their gene products alone or combination with inhibition of aberrantly activated MAP kinase signaling pathways may suppress the oncogenic activity of CRC tumors harboring KRAS or BRAF mutations. Here, KRAS is linked to colorectal carcinoma.